Autolus meets Phase II acute lymphoblastic leukemia endpoint, files for IPO Business, R&D Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%. Read more December 9, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/12/BioSpacelab12-9-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-12-09 09:30:342022-12-09 12:16:41Autolus meets Phase II acute lymphoblastic leukemia endpoint, files for IPO
